Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients. This trial heralds a new era in demonstrating the feasibility of bladder preservation for selected patients with MIBC.

中文翻译：

---

联合新辅助疗法正在为保留膀胱成为特定患者的标准铺平道路

以顺铂为基础的新辅助联合化疗，随后进行根治性膀胱切除术和盆腔淋巴结切除术，是目前符合顺铂资格的肌层浸润性膀胱癌（MIBC）患者的标准治疗方法。一项通过在化疗中添加免疫检查点抑制剂纳武单抗来测试强化治疗的 II 期试验取得了令人鼓舞的完全缓解率，这表明在选定的患者中可以实现膀胱保留治疗。这项试验预示着一个新时代的到来，证明对选定的 MIBC 患者保留膀胱的可行性。